Standout Papers

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, ... 2006 2026 2012 2019 1.5k
  1. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial (2012)
    Ian Pavord, Stephanie Korn et al. The Lancet
  2. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial (2016)
    J. Mark FitzGerald, Eugene R. Bleecker et al. The Lancet
  3. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial (2016)
    Eugene R. Bleecker, J. Mark FitzGerald et al. The Lancet
  4. The Salmeterol Multicenter Asthma Research Trial (2006)
    Harold S. Nelson, Scott T. Weiss et al. CHEST Journal
  5. Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis (2013)
    Wendy C. Moore, Annette T. Hastie et al. Journal of Allergy and Clinical Immunology
  6. Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function (2016)
    Prescott G. Woodruff, R. Graham Barr et al. New England Journal of Medicine
  7. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study (2015)
    David Price, Anna Rigazio et al. The Lancet Respiratory Medicine
  8. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies (2016)
    Héctor Ortega, Steven W. Yancey et al. The Lancet Respiratory Medicine
  9. Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts (2016)
    Michael C. Peters, Kevin McGrath et al. The Lancet Respiratory Medicine
  10. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study (2014)
    Mario Castro, Sally E. Wenzel et al. The Lancet Respiratory Medicine

Immediate Impact

5 by Nobel laureates 8 from Science/Nature 116 standout
Sub-graph 1 of 13

Citing Papers

Asthma
2023 Standout
Chronic obstructive pulmonary disease
2022 Standout
216 intermediate papers

Works of Eugene R. Bleecker being referenced

Imaging-based clusters in current smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS)
2018
Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function
2016 Standout
and 98 more

Author Peers

Author Last Decade Papers Cites
Eugene R. Bleecker 19159 14246 4916 293 24.4k
Pascal Chanez 18206 14143 5069 408 24.8k
Guy Brusselle 11692 11972 4182 389 21.9k
Sally E. Wenzel 26889 18317 9120 328 33.8k
Paul M. O’Byrne 29721 22141 6472 510 37.1k
Stanley J. Szefler 17747 14378 2299 470 23.2k
William W. Busse 25643 16406 8084 520 33.6k
Christopher E. Brightling 20456 16720 6789 405 28.0k
Charles G. Irvin 11819 9404 3582 209 18.0k
Ian Pavord 27308 23603 5857 501 33.7k
Robert F. Lemanske 14502 10561 3623 204 20.0k

All Works

Loading papers...

Rankless by CCL
2026